Placebo News and Research

RSS

New approach could lead to precise treatments for traumatic brain injury

Traumatic head injury can have widespread effects in the brain, but now scientists can look in real time at how head injury affects thousands of individual cells and genes simultaneously in mice.

5 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that the appetite-suppressant drug lorcaserin decreases risk of developing diabetes and increases the rates of remission of high blood sugar.

4 Oct 2018

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

At the 2018 Meeting of the European Association for the Study of Diabetes, Brigham and Women's Hospital investigators from the Thrombolysis in Myocardial Infarction Study Group presented diabetes-related findings from CAMELLIA-TIMI 61, a clinical trial of overweight and obese patients designed to test lorcaserin, a weight loss drug manufactured by the trial's sponsor, Eisai Inc.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

New research presented at the annual meeting of the European Association for the Study of Diabetes and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus and cardiovascular disease.

3 Oct 2018

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.

3 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Early Parkinson’s disease patients wait too long before seeking medical attention

The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease.

29 Sep 2018

Non-small cell lung cancer patients survive longer when treated with durvalumab

Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Novel therapy technique double rate of upper limb recovery in stroke patients

A novel therapy technique invented by researchers at The University of Texas at Dallas has been shown in a pilot study to double the rate of upper limb recovery in stroke patients, a leap forward in treating the nearly 800,000 Americans who suffer strokes each year.

27 Sep 2018

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Mesoblast Limited today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.

26 Sep 2018

Exercise and diet may reduce obesogenic effects of PFAS

A new study finds that perfluoroalkyl and polyfluoroalkyl substances are associated with increases in weight, but exercise and diet may reduce the obesogenic effects of these environmental contaminants.

26 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

A new study out today in the Journal of Neurology finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury.

25 Sep 2018

Lancaster professor aims to understand how genes affect smoking cessation

The Canadian Institute of Health Research has awarded $929,475 to Professor Jo Knight of Lancaster Medical School, Lancaster Data Science Institute and the Department of Psychiatry at the University of Toronto.

25 Sep 2018

Placebo News and Research

New approach could lead to precise treatments for traumatic brain injury

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

Human clinical trial of investigational calcification inhibitor generates promising results

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Early Parkinson’s disease patients wait too long before seeking medical attention

Non-small cell lung cancer patients survive longer when treated with durvalumab

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Novel therapy technique double rate of upper limb recovery in stroke patients

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Exercise and diet may reduce obesogenic effects of PFAS

New TB vaccine effective in half of the population in phase II trials

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

Lancaster professor aims to understand how genes affect smoking cessation

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News